Neuropore Therapies

Neuropore Therapies awarded Parkinson’s research grant from Michael J. Fox Foundation

Tuesday, January 31, 2017

Neuropore Therapies, a biopharmaceutical company discovering and developing novel therapeutics for the treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders, has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in support of its Toll-Like Receptor 2 (TLR2) antagonist program focused on modulating neuroinflammation and autophagy in Parkinson’s disease and other neurodegenerative diseases.

[Read More]

Neuropore, UCB enter world-wide collaboration and agreement

Monday, January 19, 2015

Neuropore Therapies, a wholly owned U.S. subsidiary of Austria-based Ever Neuro Pharma, and UCB, a Brussels, Belgium-based global biopharmaceutical company, have entered into a worldwide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders. This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein, which currently is in preclinical development and is expected to enter clinical phase I in 2015.

[Read More]